- University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane QLD
- Competing interest
- This person has declared the following competing interest:
Member of the Denosumab Advisory Board for Amgen in 2007, member of the Satrplatin Advisory Board for Pharmion in 2006, member of Pfizer’s International Steering Committee for Darafenacin(2000–2002), member of Natbio’s Medical and Biological Advisory Committee (2003–2007), member of Advisory Board for Roche Products regarding Fleroxacin (QuinodisTN) in 1992. Not presently a member of any industry boards and none of the above relate to androgen deprivation therapies. (Satraplatin is a cytotoxic drug and Denosumab is a human monoclonal antibody to Rank ligand to prevent bone metastases in prostate and other cancers. Darafenacin is an anticholinergic drug used for treatment of urinary incontinence and Fleroxacin is/was an antibiotic. Member of a group undertaking commissioned clinical trials for industry for which payment is received and used to bolster finances for research activities. About to commence a trial with abiraterone (which blocks androgen production from the adrenal) in patients with castrate-resistance prostate cancer and a study using an infrared light to destroy BPH tissue in patients primed with a porphyrin to enhance the activity of the infrared light. Hoping to undertake a further study with Amgen imminently with Denosumab in patients with castrate resistant prostate cancer. Presently doing a study with Botox for urinary incontinence and hope to participate in an extension study.